Core Insights - The top three companies by Hong Kong Stock Connect shareholding ratios are China Telecom (71.61%), Gree Power (69.82%), and Kaisa New Energy (67.97%) [1] - The largest increases in shareholding over the last five trading days were seen in the Tracker Fund of Hong Kong (+4.898 billion), Xiaomi Group-W (+2.104 billion), and Hang Seng China Enterprises (+2.034 billion) [1] - The largest decreases in shareholding over the last five trading days were recorded for Tencent Holdings (-3.674 billion), China Mobile (-2.390 billion), and Zijin Mining (-792 million) [1] Group 1: Hong Kong Stock Connect Shareholding Ratios - China Telecom (00728) holds 9.938 billion shares with a shareholding ratio of 71.61% [1] - Gree Power (01330) holds 0.282 billion shares with a shareholding ratio of 69.82% [1] - Kaisa New Energy (01108) holds 0.170 billion shares with a shareholding ratio of 67.97% [1] - Tianjin Chuangye Environmental Protection (01065) holds 0.229 billion shares with a shareholding ratio of 67.36% [1] - Other notable companies include China Shenhua (66.29%) and Southern Hang Seng Technology (65.38%) [1] Group 2: Recent Increases in Shareholding - Tracker Fund of Hong Kong (02800) saw an increase of +4.898 billion with a change of +18.6086 million shares [1] - Xiaomi Group-W (01810) increased by +2.104 billion with a change of +5.53495 million shares [1] - Hang Seng China Enterprises (02828) increased by +2.034 billion with a change of +2.19962 million shares [1] - Other companies with significant increases include Ping An Insurance (+2.027 billion) and Kuaishou-W (+1.709 billion) [1] Group 3: Recent Decreases in Shareholding - Tencent Holdings (00700) experienced a decrease of -3.674 billion with a change of -5.9645 million shares [3] - China Mobile (00941) decreased by -2.390 billion with a change of -2.9561 million shares [3] - Zijin Mining (02899) saw a decrease of -792 million with a change of -2.1294 million shares [3] - Other companies with notable decreases include China Unicom (-764 million) and Xinda Biopharmaceuticals (-596 million) [3]